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Changes in glomerular thromboxane A2 receptor expression and ligand vent the decrease in GFR [1, 3]. However, the drop in
binding following immune injury. GFR is transient and is followed by a recovery in late
Background. Thromboxane (Tx) A2 is a potent vasoconstrictor eico-
stages of injury, despite a persistently marked increasesanoid that attains high levels within nephritic glomeruli and mediates
a drop in glomerular filtration rate (GFR). In the course of nephritis, in glomerular TxA2 levels [1, 4]. This indicates that, in
however, GFR recovers despite high intraglomerular TxA2 levels. We the course of injury, changes may occur in the glomerularhypothesized that this recovery indicates a reduced responsiveness of
TxA2 receptor availability or in receptor-ligand binding,the glomerular vasculature to TxA2, and explored whether changes
in TxA2 receptor protein expression and receptor-ligand binding are thereby altering the responsiveness of the glomerular
underlying mechanisms. vasculature to endogenous TxA2. These studies wereMethods. Glomerulonephritis was induced in male Sprague-Dawley
undertaken to explore whether changes in glomerular Txrats using an antibody raised in rabbits against rat particulate glomeru-
lar basement membrane (GBM). Changes in Tx receptor levels were receptor protein expression or in receptor-ligand binding
assessed in protein lysates of glomeruli on days 3 and 7 after a single occur in a model of immune injury that resembles humanintravenous injection of the anti-GBM antibody. Ligand-binding stud-
forms of rapidly progressive glomerulonephritis and areies were performed at the same time points using isolated glomeruli
and the TxA2 receptor ligand [3H]-SQ-29,548. GFR was measured as characterized by increased glomerular Tx synthesis.
the clearance of endogenous creatinine.
Results. There was a marked increase in Tx receptor protein in the
lysates of nephritic glomeruli on days 3 and 7. In contrast, binding
METHODSsites (Bmax) of [3H]–SQ-29,548 decreased, indicating that the excess
receptor became either inaccessible to its ligand (sequestered) or de- Development of glomerular immune injury
sensitized. Daily administration of the Tx synthase inhibitor Furegrel-
ate starting prior to injection of anti-GBM antibody prevented the Injury was induced by antibody raised against rat glo-
decrease in [3H]–SQ-29,548 binding. Furegrelate treatment starting in merular basement membrane (GBM). Male Sprague-
an established stage of nephritis had no effect. In these animals, GFR
Dawley rats weighing 120 to 200 g were immunized intra-was lower than nephritic controls not treated with Furegrelate.
Conclusions. These observations indicate that in the course of glo- peritoneally with 1 mg rabbit IgG emulsified in complete
merulonephritis, there is a marked increase in glomerular Tx receptor Freund’s adjuvant and given in a total volume of 0.5 ml.
expression. The enhanced intraglomerular TxA2 synthesis causes either Five days following this immunization, animals receiveda sequestration or desensitization of its receptor. As a result, access
of unbound TxA2 to efferent arterioles may become facilitated, and a single intravenous injection of a subnephritigenic dose
constriction of these arterioles may preserve GFR. of rabbit immune serum raised against rat GBM pre-
pared as previously described [5]. The dose of immune
serum was 0.15 ml/100 g body weight and was insufficient
We and other investigators have previously shown that by itself to cause significant proteinuria when given to
in various forms of glomerular immune injury, there is animals not immunized with rabbit IgG (subnephrito-
enhanced thromboxane (Tx) A2 production in glomeruli genic dose). Prior to injection, the rabbit antirat GBM
[1, 2]. In early stages of injury, TxA2 causes renal vaso- immune serum was heat inactivated and filtered through
constriction and mediates the drop in glomerular filtra- 1.2 mmol filters. Control animals were immunized with
tion rate (GFR) [1, 3]. Thus, pharmacologic inhibition rabbit IgG in complete Freund’s adjuvant and were sub-
of Tx synthase or antagonism of the TxA2 receptor pre- sequently given an intravenous injection of nonimmune
rabbit serum. Studies (discussed later here) were per-
formed on days 3 and 7 following injection of the antiratKey words: glomerular basement membrane, glomerular filtration rate,
prostaglandin H2, Furegrelate, [3]H-SQ 29,548, glomerulonephritis. GBM serum or the nonimmune rabbit serum. The eve-
ning prior to the study, animals were placed in metabolicReceived for publication December 30, 1997
cages for urine collection to assess urinary protein excre-and in revised form July 21, 1998
Accepted for publication July 27, 1998 tion. After completion of this collection, animals were
nephrectomized in order to isolate glomeruli by differen- 1999 by the International Society of Nephrology
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tial sieving of finely minced cortex, as previously de- membranes were stripped and reprobed with an antiactin
antibody (Sigma Chemical Co., St. Louis, MO, USA).scribed [1, 4]. Glomerular preparations of 95% to 98%
purity were routinely obtained and processed either for
TxA2 receptor-binding studies in isolated glomeruliassessment of changes in glomerular Tx receptor protein
by Western blot analysis or for binding studies (discussed On days 3 and 7 following administration of the anti-
GBM antibody or nonimmune serum, nephrectomieslater in this article).
were performed, and kidneys were placed in chilled TBS,
Western blot analysis of glomerular Tx receptor protein pH 7.5. Total glomerular protein was determined in an
aliquot of each glomerular suspension after sonication.Preparations of isolated glomeruli were suspended in
lysis buffer (50 mmol HEPES, 150 mmol sodium chlo- Protein was measured using a colorimetric method.
To assess TxA2 receptor binding, aliquots of glomeruliride, 1.5 mmol magnesium chloride, 1 mmol EGTA, 10%
glycerol, 1% Triton X-100) and were sonicated for one (100 to 150 mg of protein) were incubated in a final
volume of 0.25 ml in TBS at 258C with defined amountsminute at 48C. The lysis buffer contained the following
protease inhibitors: aprotinin 1 mg/ml, leupeptin 1 mg/ (0.55 to 17.6 nmol) of the TxA2 receptor ligand [3H]-
SQ-29,548 (New England Nuclear, Danvers, MA, USA;ml, phenylmethyl-sulfonylfluoride 1 mmol. Lysates were
clarified by centrigation at 15,000 g for 30 minutes at specific activity 46 Ci/mmol). Preliminary binding kinetics
showed that binding of this ligand reached a maximum48C, and concentrations of total protein in lysates were
measured by a colorimetric method. Defined amounts within 20 to 30 minutes. All subsequent equilibrium-bind-
ing studies were performed at 30 minutes. The bindingof glomerular protein (50 mg) were subsequently electro-
phoresed on 8% Tris-glycine sodium dodecyl sulfate gels reaction was stopped by a 20-fold dilution of the reactants
using ice-cold buffer. Samples were then rapidly filtered(Novex, San Diego, CA, USA). Rabbit platelet mem-
brane lysates (rich in Tx receptor protein) were electro- (Schleicher and Schuell, #30), and trapped glomeruli
were washed with 2 to 5 volumes of ice-cold buffer. Filtersphoresed in parallel as a positive control.
Electrophoresis was performed under 100 V at 30 mA with the trapped glomeruli were assessed for [3H]-SQ-
29,548 binding by radioactivity counting in a liquid scin-for 90 minutes. Subsequently, electrophoresed proteins
were transferred overnight onto nitrocellulose membranes tillation counter. Measurements for each concentration
of [3H]-SQ-29,548 employed were performed in dupli-at room temperature. Following completion of the trans-
fer, membranes were blocked with 3% gelatin in Tris- cate or triplicate. Nonspecific binding was determined
in the presence of unlabeled excess SQ-29,548 (Biomol; 5buffered saline (20 mmol Tris base, 500 mmol sodium
chloride, pH 7.5) containing 0.2% Tris-buffered saline mmol). Equilibrium binding was analyzed by established
Scatchard analysis methods to calculate specific bindingTween-20 (TTBS). Membranes were subsequently incu-
bated with a polyclonal antibody (raised in rabbits) against sites (Bmax) and dissociation constant (Kd).
the TxA2/prostaglandin H2 (PGH2) receptor. The anti-
Thromboxane synthesis inhibitionbody was dissolved in TTBS containing 1% gelatin at
1:200 final dilution. The antibody was raised against the To assess the extent to which intraglomerular Tx, the
levels of which are increased following anti-GBM anti-TxA2/PGH2 receptor protein, a 55 kDa protein purified
from platelets using ligand affinity chromatography. The body-induced injury, regulates receptor binding sites in
nephritic glomeruli, its synthesis was inhibited using theantibody was raised by Borg et al [6] and was a generous
gift from Dr. G.C. LeBreton (Department of Pharmacol- specific Tx synthase inhibitor Furegrelate (5-[3-pyridi-
nylmethyl]-benzofurancarboxylic acid). Tx was inhibitedogy, University of Illinois). We have previously used this
antibody to immunolocalize the TxA2 receptor in the either prior to the onset of glomerular immune injury
(before administration of the anti-GBM antibody) or inrat kidney [7]. Following overnight incubation with this
antibody, membranes were washed and incubated for 1 a well-established stage of injury. The former approach
prevented an increase of intraglomerular Tx levels fol-hour with a secondary antibody (horseradish peroxidase-
conjugated goat antirabbit IgG antibody; Amersham, lowing injury and therefore prevented exposure of glo-
merular TxA2 receptors to excess TxA2. The latter ap-Arlington Heights, IL, USA) dissolved in TTBS contain-
ing 1% gelatin at a final dilution of 1:4000. After washing, proach allowed an increase of intraglomerular Tx levels
to occur for a period of six days following injury, thusmembranes were incubated for two minutes with an en-
hanced chemiluminance reagent system (Amersham) at exposing TxA2 receptors to excess TxA2. To inhibit Tx
synthesis prior to onset of immune injury, Furegrelateroom temperature. Membranes were subsequently ex-
posed to a Kodak Biomax MR imaging film to detect 20 mg/kg body weight was given intravenously daily be-
ginning 24 hours before injection of the anti-GBM anti-antibody binding. Prestained protein markers of known
molecular mass were electrophoresed and blotted simul- body and continuing daily for seven days. To inhibit Tx
synthesis in an established stage of injury, Furegrelatetaneously. To assess whether equal amounts of glomerular
lysate protein were loaded in each well of the SDS gel, 20 mg/kg body weight was given intravenously only on
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days 6 and 7 following injection of the anti-GBM anti-
body. The efficacy of Furegrelate to inhibit Tx synthesis
both systemically and at the glomerular level was as-
sessed by determinations of the TxB2 metabolite in serum
(platelet-derived Tx) and in isolated glomeruli.
Control animals received identical amounts of Fure-
grelate and nonimmune rabbit serum instead of the anti-
GBM serum. Levels of TxB2, the stable metabolite of
TxA2, were determined in serum samples (reflecting
platelet-derived Tx) or in isolated glomeruli. The glo-
meruli were suspended in 2 ml RPMI 1640 and incubated
under constant stirring at 378C for 30 minutes. At the
end of this incubation, an aliquot of the medium was
Fig. 1. Urine protein excretion in control and nephritic animals, andassayed directly for TxB2 using a specific radioimmuno- in nephritic animals treated with Furegrelate given either prior to or
assay for this eicosanoid as we and others have previously following administration of anti-GBM antibody. Neither treatment pro-
tocol reduced protein excretion. *P , 0.05 compared to controls.described [1, 4].
Platelet-depletion studies
These were performed to explore whether circulating
platelets that can infiltrate glomeruli following deposi-
tion of the anti-GBM antibody and complement activa-
tion significantly contribute to levels of TxA2 receptor
expression in glomerular lysates.
To deplete circulating platelets, a rabbit antirat throm-
bocyte immune serum (Accurate Chemical and Science
Corporation, Westbury, NY, USA) was given as a single
intraperitoneal injection of 0.5 ml/100 g body weight.
This resulted in a marked and selective systemic platelet
depletion within 18 hours (the counts, assessed using a
hematology analyzer, fell from 890 6 70 to 9 6 3 3 103
platelets/mm3; N 5 5). Animals that maintained platelet
Fig. 2. Glomerular Tx synthesis, assessed as production of the immuno-counts of less that 10 3 103/mm3 (N 5 3) were subse-
assayable metabolite TxB2, on days 3 and 7 following administrationquently given anti-GBM antibody, and glomerular ly- of the anti-GBM antibody. *P , 0.05 compared to control.
sates were prepared as described earlier for Western
blot analysis of TxA2 receptor expression.
Determination of glomerular filtration rate lecular Dynamics, Sunnyvale, CA, USA) interfaced with
a software imaging system (Image Quant). Bands shownThe glomerular filtration rate (GFR) was assessed as
reflect TxA2 receptor protein (55 kDa) levels and actinclearance of endogenous creatinine. Creatinine was mea-
levels (marker for equal protein loading) in glomerularsured in timed urine collections (18 to 24 hr) and in
lysates.corresponding serum samples. Creatinine concentration
in the urine and serum samples was measured colorimet-
rically by the method of Siedel, Mollering and Ziegen- RESULTS
horn [8], which is based on the combined use of creatini-
All animals with anti-GBM antibody-mediated injurynase, creatinase, and sacrosine enzymes. The oxidation
developed a proliferative glomerulonephritis with markedof sacrosine produces hydrogen peroxide, which is used
proteinuria. Increased urinary protein excretion was pres-in the indicator reaction to produce the resultant color.
ent at both time points of study (days 3 and 7), and treat-Glomerular TxB2 synthesis, Bmax and Kd values, and
ment with the Tx synthase inhibitor, Furegrelate, givenGFR were expressed as mean 6 standard deviation. Sta-
either prior to onset of injury or on days 6 and 7 followingtistical differences among the various treatment groups
onset of injury, had no effect on the magnitude of pro-were assessed using t-test statistics for unpaired observa-
teinuria (Fig. 1).tions. The Western blots shown are representative of inde-
In glomeruli isolated on days 3 or 7 following adminis-pendent blots performed on glomerular protein lysates,
tration of the anti-GBM antibody, TxA2 synthesis, as-each originating from three individual animals assigned
sessed as immunoassayable TxB2 metabolite, was in-to the experimental condition or treatment described.
All blots were scanned by a scanner/densitometer (Mo- creased (Fig. 2).
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Fig. 3. Western blot analysis of TxA2 receptor protein (A; 55 kDa)
performed in lysates of glomeruli isolated from rats that received nonim-
Fig. 4. Effect of depletion of circulating platelets on levels of TxA2mune rabbit serum (lane 1) or anti-GBM antibody and sacrificed on
receptor protein in glomerular lysates assessed on day 3 of nephritis.day 3 (lane 2), or day 7 (lane 3). A positive control consisting of a
(A) Lane 1, glomeruli from a non-nephritic animal; lane 2, glomeruliplatelet membrane lysate is shown in lane 4. (B) Actin levels are also
from a platelet-replete nephritic animal; lane 3, glomeruli from a plate-shown as a marker of equal protein loading.
let-depleted nephritic animal. (B) Actin levels as a marker of equal
protein loading are shown.
Changes in abundance of glomerular Tx receptor pro-
tein (Western blot analysis) are shown in Figure 3. A
Figure 9 shows the effect of TxA2 synthesis inhibitionmarked increase in receptor protein without a change
using Furegrelate treatment initiated prior to onset ofin actin levels (control for equal protein loading) is ap-
immune injury on the abundance of SQ-29,548 bindingparent in nephritic glomeruli (days 3 and 7) compared
sites (Bmax) in isolated glomeruli. In glomeruli of nephriticwith control glomeruli. The effect of platelet depletion
animals not treated with Furegrelate, SQ-29,548 bindingon levels of TxA2 receptor in nephritic glomeruli (day
sites were lower than that in glomeruli of nonnephritic3) is shown in the Western blot of Figure 4. There was
controls. Binding sites in glomeruli of Furegrelate-treatedno significant decrement in receptor levels in protein
nephritic animals were no different from those obtainedlysates of glomeruli isolated from platelet-depleted ne-
in non-nephritic glomeruli. Thus, inhibition of endoge-phritic animals (lane 3) compared with those in platelet-
nous Tx prior to the onset of injury prevented the de-replete nephritic controls (lane 2).
crease in receptor-ligand binding in nephritic glomeruli.In Figure 5, representative Scatchard analysis graphs
Figure 10 shows the effect of inhibition of glomerularusing the TxA2 receptor ligand [3H]-SQ-29,548 are shown
Tx synthesis (Furegrelate treatment) applied on daysand demonstrate the Bmax and Kd values obtained in each
6 and 7 following the onset of immune injury on theexperimental condition. [3H]-SQ-29,548 binding sites
abundance of binding sites for the SQ-29,548 ligand in(Bmax values) assessed on days 3 and 7 of the injury
glomeruli isolated on day 7. In glomeruli of Furegrelate-in isolated glomeruli progressively decreased without a
treated nephritic animals, SQ-29,548 binding sites (Bmaxchange in affinity constant Kd (Fig. 6).
value) remained depressed to a level similar to that ob-Furegrelate treatment initiated either prior to or fol-
tained in glomeruli from nephritic animals that did notlowing the onset of injury inhibited glomerular Tx syn-
receive Furegrelate.thesis to a similar extent (shown in Fig. 7). Neither treat-
The effect of Tx synthesis inhibition (Furegrelatement protocol had an effect on glomerular TxA2 receptor
protein levels (Fig. 8). treatment) on GFR is shown in Figure 11. In nephritic
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Fig. 5. Representative Scatchard analysis plots obtained in preparations of glomeruli isolated from: a non-nephritic rat (A), a nephritic rat on
day 7 of nephritis (B), a nephritic rat given Furegrelate 24 hours prior to administration of anti-GBM antibody and daily thereafter until day 7
of nephritis (C ), and a nephritic rat given Furegrelate only on days 6 and 7 following anti-GBM antibody and studied on day 7 of nephritis (D).
The Kd and Bmax values obtained are shown.
animals that received Furegrelate prior to administration has recently been characterized and was shown to con-
tain seven transmembrane domains characteristic of G-of anti-GBM antibody and daily thereafter, GFR re-
protein–coupled receptors [9]. This receptor is linkedmained at levels no different than those in nephritic
with the inositol trisphosphate/Ca21 signal transductioncontrols that did not receive Furegrelate. In nephritic
system [9].animals that received Furegrelate on only days 6 and
Using an antibody raised against purified TxA2/PGH27 of nephritis, GFR was lower than that in nephritic
receptor protein, we have recently characterized the dis-controls.
tribution of this receptor in the rat nephron. We demon-
strated that in the glomerulus, the receptor is mainly
DISCUSSION located in the endothelium of the glomerular vasculature
Since its original discovery, TxA2 has been recognized [7]. This location may be strategic in that the receptor
as a potent vasoconstrictor eicosanoid. The biological becomes readily available to bind TxA2 originating either
actions of TxA2 occur following binding to a specific cell from blood-borne cells (platelets and leukocytes) or from
endogenous glomerular cells in various forms of glomer-membrane receptor. The rat kidney Tx receptor protein
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Fig. 6. Changes in abundance of specific binding sites (Bmax; A) for the
TxA2 receptor ligand SQ-29,548 assessed in isolated glomeruli on days Fig. 8. Effect of the Furegrelate treatment protocols employed on TxA23 and 7 of nephritis. Changes in dissociation constant (Kd; B) are shown receptor levels in glomerular protein lysates. Shown are the receptorin parallel. *P , 0.05 versus controls. protein (55 kDa; A) and actin as a marker of equal protein loading (B).
Fig. 7. Effect of the TxA2 synthase inhibitor, Furegrelate, on glomeru- Fig. 9. Effect of inhibition of endogenous Tx synthesis starting beforelar Tx synthesis assessed by measuring the production of the immunoas- injection of the anti-GBM antibody and continuing daily for seven dayssayable metabolite TxB2. Day 7 is defined as the glomerular TxB2 (Daily Furegrelate) on abundance of ligand (SQ-29,548) binding sitesproduction on day 7 following injection of anti-GBM antibody. Daily (Bmax) in glomeruli isolated on day 7. Day 7 is the Bmax in glomeruliFuregrelate is the Furegrelate treatment starting 24 hours before injec- isolated 7 days following anti-GBM antibody. These animals did nottion of the anti-GBM antibody and continued daily thereafter until receive Furegrelate. *P , 0.05 compared to control (non-nephritic)point of study (day 7). Day 6 and 7 Furegrelate is the Furegrelate glomeruli.treatment given only on days 6 and 7 following injection of the anti-
GBM antibody. *P , 0.05 compared to day 7.
the GBM or against mesangial cells, we and other investi-
gators have shown that TxA2 mediates renal vasocon-ular injury. Levels of Tx in glomeruli are increased in
various forms of antibody-mediated injury [1–3], drug- striction and the decrease in GFR at early stages of
injury. Thus, Tx synthase inhibitors at doses sufficientinduced injury (aminonucleoside of puromycin, cyclos-
porine) [10, 11], and diabetic glomerulopathy [12]. to block TxA2 synthesis at the glomerular level or TxA2
receptor antagonists prevent the drop in GFR [1, 3].Using models of injury mediated by antibodies against
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When changes in Tx receptor protein were examined
by Western blot analysis, a marked increase in abun-
dance of this protein was found in lysates of nephritic
glomeruli at the time points of injury studied (Fig. 3).
One would therefore also expect an increase in ligand-
binding sites in isolated glomeruli, as assessed in these
studies using the receptor ligand SQ-29,548. Instead,
binding sites were decreased (Fig. 6). This confirms simi-
lar observations made in glomeruli of mice with murine
lupus nephritis [13]. A possible explanation is that the
enhanced synthesis of endogenous TxA2 within glomer-
uli following immune injury was of such magnitude that
it occupied ligand-binding sites in the receptor proteinFig. 10. Effect of inhibition of endogenous Tx synthesis applied only
to an extent that availability of sites to bind the SQ-on days 6 and 7 following injection of the anti-GBM antibody (Days 6 &
7 Furegrelate) on ligand (SQ-29,548) binding sites (Bmax) in glomeruli 29,548 ligand was reduced.
isolated on day 7. Day 7 is the Bmax in glomeruli isolated 7 days following To address this issue and because ex vivo measurementanti-GBM antibody. These animals did not receive Furegrelate. *P ,
of glomerular Tx synthesis, as done in these studies (Fig.0.05 compared to control (non-nephritic) glomeruli.
2), does not reflect the magnitude of TxA2 levels attained
within nephritic glomeruli, we employed an endogenous
Tx synthesis–inhibition approach. Furegrelate treatment
of nephritic animals initiated prior to administration of
the anti-GBM antibody prevented the increase in glo-
merular Tx but failed to increase binding sites for the
SQ-29,548 ligand (Bmax) in their glomeruli above those in
normal glomeruli (Fig. 9). This indicates that the excess
receptor protein found in nephritic glomeruli was appar-
ently inaccessible to the SQ-29,548 ligand. A likely expla-
nation is internalization (sequestration) of the excess
receptor protein following binding of ambient (intra-
glomerular) TxA2. Thus, in glomeruli of Furegrelate-
treated nephritic animals, SQ-29,548 binding sites (Bmax)
were restored to control levels (Fig. 9), indicating that
the enhanced production of endogenous TxA2 was re-
quired for receptor internalization to occur.
When inhibition of endogenous Tx synthesis was initi-
ated at established stages of injury at which the increase
of intraglomerular Tx levels had already occurred, it
failed to restore SQ-29,548 binding sites (Bmax) in ne-Fig. 11. Effect of inhibition of endogenous Tx synthesis on GFR using
phritic glomeruli to control levels (Fig. 10). This indicatesthe two Furegrelate treatment protocols described in the text. Symbols
are: ( ) GFR was measured in non-nephritic control animals; ( ) that exposure of Tx receptors to the high levels of intrag-
GFR in nephritic animals on day 7 following injection of anti-GBM lomerular TxA2 attained for a period of six days priorantibody; ( ) GFR in nephritic animals given Furegrelate 24 hours
to its inhibition resulted in an irreversible sequestrationprior to injection of anti-GBM antibody and daily thereafter until day
7 of nephritis; ( ) GFR in nephritic animals given Furegrelate only or a desensitization of the receptor. TxA2–induced recep-
on days 6 and 7 following injection of anti-GBM antibody. *P , 0.05 tor densitization associated with a decrease in receptorcompared to non-nephritic controls; **P , 0.05 compared to nephritic
numbers was previously shown in platelet suspensionsanimals not given Furegrelate.
exposed to TxA2 mimetics [14]. An alternative mecha-
nism is TxA2-mediated phosphorylation of its receptor
via protein kinase C (PKC) activation. The TxA2 recep-
However, in late stages of injury, GFR recovers despite tor gene contains two alternatively utilized promoters,
a persistently marked increase in glomerular TxA2 levels promoter I and II, of which promoter I contains a phor-
[1, 4]. This indicates a change in the responsiveness of the bol ester response element [15]. Phorbol myristate ace-
glomerular vasculature to TxA2 in the course of immune tate–induced PKC stimulation reduces TxA2 receptor
injury and prompted us to explore whether changes in ligand binding in the platelet-like human erythroleuke-
the abundance of glomerular TxA2 receptor protein or in mia cells [16]. In these cells, an addition of PKC to
membrane preparations of human embryonic kidneyreceptor–ligand interactions are underlying mechanisms.
Bresnahan et al: Thromboxane A2 receptor in nephritis146
cells transfected with the TxA2 receptor reduces recep- within nephritic glomeruli as a result of TxA2 synthase
inhibition.tor-ligand binding, whereas inhibition of PKC increases
Our studies provide the first in vivo evidence that inreceptor-ligand binding [16]. In the course of glomerular
glomerulonephritis endogenous TxA2 reduces the ligand-immune injury, PKC activation within glomeruli can oc-
binding capacity of its intraglomerular receptor, and thatcur by a number of agonists. These include TxA2 itself,
under these circumstances it may preserve GFR. Ourcytokines, and growth factors. We have shown that TxA2
observations can be summarized as follows: In the coursestimulates the generation of diacyl glycerol and PKC
of glomerular immune injury, a marked increase in abun-activity in glomerular mesangial cells [17]. Growth fac-
dance of TxA2 receptor protein occurs in glomeruli. Thetors identified in nephritic glomeruli that can activate
excess receptor protein becomes either internalized orPKC include basic fibroblast growth factor, platelet-
desensitized by endogenous TxA2. This may result inderived growth factor, and transforming growth factor-
increased intraglomerular levels of unbound TxA2 andb. Of these factors, basic fibroblast growth factor was
facilitate its access to efferent arterioles. TxA2-mediatedshown to reduce TxA2 receptor-ligand binding in human
constriction of these arterioles may maintain GFR.erythroleukemia cells [16].
These observations are important when consideringThe implication of these observations is that TxA2
TxA2 inhibition or antagonism as an anti-inflammatorygenerated within glomeruli in the course of immune in-
strategy in rapidly progressive forms of glomerulone-jury may remain unbound because of sequestration or
phritis. Such treatment may not have the expected bene-desensitization of its receptor. These events could facili-
ficial effect, that is, preservation of GFR, because oftate access of unbound TxA2 to postglomerular (effer-
changes in intraglomerular TxA2 receptor and in recep-ent) arterioles causing constriction. This would result in
tor–ligand interactions.increased hydrostatic pressure within glomerular capil-
laries, thereby preserving GFR. Under these circum-
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